Dyno Therapeutics Emerges With Novartis, Sarepta Deals For Novel AAV Capsids

Dyno raised $9m in 2018 but came out of stealth mode with deals worth up to $2bn based on its platform using high throughput biology, AI and machine learning to engineer next-generation AAV capsids.

Adeno-associated virus serotype 1. Virus is used as a vector for gene therapy
Dyno's novel AAV capsids could expand gene therapy's reach • Source: Shutterstock

The idea for Dyno Therapeutics Inc.’s CapsidMap platform for developing novel capsids for adeno-associated virus (AAV) vectors came to fruition after CEO and co-founder Eric Kelsic joined the Harvard University lab of George Church as a post-doc in 2015. The company officially launched in 2018 with $9m in seed funding and now it is emerging from stealth mode with gene therapy partnerships that Dyno says are worth up to $2bn in upfront payments, research funding and milestone fees.

Those collaborations announced on 11 May give Novartis AG and Sarepta Therapeutics Inc. access to CapsidMap, which combines...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Deals

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.